BlackRock Investment Management’s Akebia Therapeutics AKBA Stock Holding History

BlackRock Investment Management’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$1.52M	Sell	146,146 -205	-0.1%	-$1.76K	﹤0.01%	2406
2016 Q3	$1.32M	Buy	146,351 +2,043	+1%	+$17.4K	﹤0.01%	2480
2016 Q2	$1.08M	Buy	144,308 +13,708	+10%	+$120K	﹤0.01%	2566
2016 Q1	$1.18M	Buy	130,600 +34,149	+35%	+$277K	﹤0.01%	2374
2015 Q4	$1.25M	Buy	96,451 +1,847	+2%	+$18.8K	﹤0.01%	2438
2015 Q3	$914K	Buy	94,604 +3,877	+4%	+$35.6K	﹤0.01%	2663
2015 Q2	$934K	Buy	90,727 +68,221	+303%	+$582K	﹤0.01%	2814
2015 Q1	$250K	Sell	22,506 -506	-2%	-$5.39K	﹤0.01%	3177
2014 Q4	$268K	Buy	23,012 +112	+0.5%	+$1.61K	﹤0.01%	3204
2014 Q3	$507K	Buy	22,900 +430	+2%	+$9.88K	﹤0.01%	2965
2014 Q2	$624K	Buy	+22,470	New	+$541K	﹤0.01%	2921

Other funds holding AKBA

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

ACP

Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return

BlackRock Investment Management's AKBA Position: Q4 2016 in Review

BlackRock Investment Management reduced its Akebia Therapeutics (AKBA) stake by 0.14% in Q4 2016, selling an estimated $1.76K and leaving 146,146 shares worth $1.52M. The position accounts for ﹤0.01% of the portfolio, ranked #2406.

BlackRock Investment Management first reported a position in AKBA in Q2 2014 and has held it in 11 quarters since. 94 funds tracked by Wall St. Rank hold AKBA as of Q4 2016.

BlackRock Investment Management held 146,146 shares of Akebia Therapeutics worth $1.52M as of Q4 2016.
BlackRock Investment Management sold 205 Akebia Therapeutics shares in Q4 2016, an estimated $1.76K.
Akebia Therapeutics made up ﹤0.01% of BlackRock Investment Management's portfolio in Q4 2016, its #2406 holding.
BlackRock Investment Management first reported a position in Akebia Therapeutics in Q2 2014 and has held it in 11 quarters since.
94 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q4 2016.

Based on BlackRock Investment Management's 13F filing for Q4 2016, filed 10 Feb 2017.